Challenges With PARP Inhibitors in Ovarian Cancer

Opportunities and Challenges in Early Breast Cancer: Do PARP Inhibitors Have a Role?Подробнее

Doc Talks - Gynecologic Cancer in 2022: Victories and ChallengesПодробнее

Innovative and Emerging Trials in Ovarian CancerПодробнее

Ovarian Cancer: PARP Inhibitors and Beyond (Webinar) May 8th World Ovarian Cancer DayПодробнее

Professor Gordon Jayson: treating ovarian cancer with anti-angiogenic agentsПодробнее

Learn all about PARP inhibitors with Dr Jon Krell, Consultant Medical OncologistПодробнее

Castration Resistant Prostate Cancer - Developments and Challenges from 2020Подробнее

Tackling Platinum Resistant Ovarian CancerПодробнее

Integrating New Research Information into Current Clinical Care — Ovarian CancerПодробнее

Changing Paradigms for the Treatment of Ovarian CancerПодробнее

Advanced Breast Cancer: Challenges in Pathways DevelopmentПодробнее

Ursula Matulonis on PARP inhibitors: opportunities, challenges and new directionsПодробнее

Dr. Chon on Challenges With Maintenance Therapy in Ovarian CancerПодробнее

Challenges With Targeted Therapies in Ovarian CancerПодробнее

Treatment and Issues For Triple Negative Breast Cancer-May 14, 2020Подробнее

PARP Inhibitor in Ovarian CancerПодробнее

Benefits and challenges of using PARP inhibitors to treat metastatic breast cancerПодробнее

ACTG Dinner Symposium Highlights | Beyond BRCA testing – does HRD matter? | Prof Michael FriedlanderПодробнее

Metastatic granulosa cell tumours and PARP inhibitorsПодробнее

Gynecologic Cancer Education: Immunotherapy & YouПодробнее